Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Biohaven Ltd. (NYSE:BHVN) have been given an average rating of “Moderate Buy” by the seventeen research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $25.5714.

BHVN has been the subject of a number of recent analyst reports. Royal Bank Of Canada decreased their price target on shares of Biohaven from $19.00 to $9.00 and set a “sector perform” rating for the company in a report on Thursday, November 6th. HC Wainwright reissued a “neutral” rating and issued a $11.00 price objective on shares of Biohaven in a research report on Friday, December 26th. UBS Group cut shares of Biohaven from a “buy” rating to a “neutral” rating and cut their target price for the company from $26.00 to $11.00 in a research note on Wednesday, November 26th. Morgan Stanley cut their price objective on shares of Biohaven from $26.00 to $21.00 and set an “overweight” rating for the company in a research report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. lowered their price target on Biohaven from $47.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, November 20th.

Biohaven Price Performance

NYSE BHVN opened at $11.85 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 1.91. The stock has a market capitalization of $1.25 billion, a PE ratio of -1.56 and a beta of 1.14. Biohaven has a 12-month low of $7.48 and a 12-month high of $44.28. The company has a 50 day moving average price of $11.05 and a two-hundred day moving average price of $13.13.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.91) by $0.27. As a group, equities analysts predict that Biohaven will post -8.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Biohaven

In other Biohaven news, CAO George C. Clark purchased 17,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was purchased at an average price of $8.52 per share, for a total transaction of $144,840.00. Following the completion of the purchase, the chief accounting officer directly owned 20,000 shares in the company, valued at approximately $170,400. This trade represents a 566.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John W. Childs bought 3,333,333 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The shares were bought at an average price of $7.50 per share, with a total value of $24,999,997.50. Following the transaction, the director directly owned 5,653,904 shares in the company, valued at $42,404,280. This trade represents a 143.64% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 4,416,999 shares of company stock worth $33,144,833 over the last three months. 16.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biohaven

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sigma Planning Corp boosted its stake in Biohaven by 9.2% in the fourth quarter. Sigma Planning Corp now owns 13,613 shares of the company’s stock worth $154,000 after purchasing an additional 1,146 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in Biohaven by 37.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 18,909 shares of the company’s stock worth $213,000 after buying an additional 5,160 shares in the last quarter. Inscription Capital LLC bought a new stake in Biohaven during the 4th quarter worth about $157,000. Vanguard Group Inc. increased its position in Biohaven by 52.9% in the 4th quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock valued at $49,630,000 after acquiring an additional 1,520,756 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Biohaven by 21.6% in the fourth quarter. Arizona State Retirement System now owns 31,234 shares of the company’s stock worth $353,000 after acquiring an additional 5,551 shares during the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.